Exacis Biotherapeutics Makes Strategic Investment In Manufacturing by Hiring Head of Technical Operations and Securing Space in a GMP Cleanroom Facility Recently Completed by Factor Bioscience
Exacisis partnering with parent Factor Bioscience toproduce its iPSC-derived CAR-T and NK cells within a GMP cleanroomfacilitybuilt by Factor,and Exacis has hiredBryan Jones PhD as its Head of Technical Operations.
CAMBRIDGE, Mass., July 1, 2021 /PRNewswire/ -- Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced two significant advances in its manufacturing capabilities. Exacis is partnering with parent Factor Bioscience to produce its iPSC-derived CAR-T and NK cells within a GMP cleanroom facility built by Factor, and Exacis has hired Bryan Jones PhD as its Head of Technical Operations.
Exacis' parent company, Factor Bioscience, recently completed construction of a 5,000 square foot GMP cleanroom facility at its Cambridge, Massachusetts headquarters. The facility includes two ISO Class 7 cleanrooms and is designed to enable production of advanced mRNA, gene-editing, and cell therapy products to support all phases of clinical development. Exacis will use this new facility to produce its allogeneic mRNA engineered cell-therapy product candidates for non-clinical and clinical testing.
Exacis' next generation approach avoids the use of DNA and viruses and instead uses proprietary, innovative mRNA-based technology. This technology is used for generating iPSCs and for performing gene editing to create potent, targeted, allogeneic (off the shelf) cell therapy products, termed ExaCAR-T™ and ExaCAR-NK™ cells. The company anticipates that the Factor GMP cleanroom facility will have sufficient capacity to support its programs through late-stage clinical development.
Matthew Angel, PhD, CEO of Factor Bioscience, Exacis' parent company, added, "We invested in constructing our GMP cleanroom facility to give our partners more control over the manufacturing aspects of their cell-therapy programs. We look forward to supporting Exacis as it advances its engineered NK-cell and T-cell programs through clinical development."
Bryan Jones, PhD, Head of Technical Operations
Dr. Jones joins the company with 30 years of drug development experience in a variety of roles including at the C-suite level which allows him to contribute across many dimensions. Most recently, he was Chief Operating Officer at Sollis Therapeutics. Immediately prior, he was Vice President of Operations at Sorrento Therapeutics, a leading therapeutic antibody company and one of the early adopters of cell therapy. Dr. Jones will oversee the buildout of the Manufacturing and Quality Operations working alongside Factor Bioscience in the new facility.
"The high cost and long lead times required for cell therapy manufacturing are major issues that have hindered the progress of developing new treatments," said Dr. Jones. "The Exacis technology brings several significant advances that will allow for greater adoption of these highly targeted medicines."
Exacis CEO Gregory Fiore MD commented, "We are excited to announce these major steps forward in our ability to maintain control of our own cell supply and its quality. Adding Bryan as head of Technical Operations and securing a dedicated GMP manufacturing capacity within the Factor facility allows us to produce our unique and high quality cells on our own timeline as we progress toward the clinic."
About Exacis Biotherapeutics
Exacis is a development stage immuno-oncology company focused on harnessing the human immune system to cure cancer by engineering next generation, off-the-shelf NK and T cell therapies aimed at liquid and solid tumors. Exacis was founded in 2020 with an exclusive license to a broad suite of patents covering the use of mRNA based cell reprogramming and gene editing technologies.
ExaNK™, ExaCAR-NK™ and ExaCAR-T™ utilize mRNA cell reprogramming and mRNA gene editing technologies developed and owned by Factor Bioscience. Exacis has an exclusive license to the Factor Bioscience technology for engineered NK and T cell products derived from iPSCs for use in oncology and holds all global development and commercial rights for these investigational candidates.
About Factor Bioscience
Founded in 2011, Factor Bioscience develops technologies for engineering cells to advance the study and treatment of disease. Factor Bioscience is privately held and is headquartered in Cambridge, MA. For more information, visit www.factorbio.com.
About T and Natural Killer (NK) Cell Therapies
T and NK cells are types of human immune cells that are able to recognize and destroy cancer cells and can be modified through genetic engineering to target specific tumors.
View original content:SOURCE Exacis Biotherapeutics Inc.
